Search

Your search keyword '"Parvin Kumar Goel"' showing total 5 results
Start Over Author "Parvin Kumar Goel" Language undetermined
5 results on '"Parvin Kumar Goel"'

1. Serum Gamma glutamyltransferase (GGT) in coronary artery disease: Exploring the Asian Indian connection

Author

Kunal Kumar Singh, Parvin Kumar Goel, Aditya Kapoor, and Satyendra Tewari

Subjects
medicine.medical_specialty, RD1-811, biology, business.industry, Asian Indian, medicine.disease, Connection (mathematics), Coronary artery disease, RC666-701, Internal medicine, biology.protein, Cardiology, Diseases of the circulatory (Cardiovascular) system, Medicine, Surgery, Gamma-glutamyltransferase, Cardiology and Cardiovascular Medicine, business
Published
2021

2. TCT-64 Two-Year Clinical and Imaging Outcomes of Thin Strut Sirolimus-Eluting Bioresorbable Vascular Scaffolds in De Novo Coronary Artery Lesions: The MeRes-1 Trial

Author

Samuel Mathews, Praveen Chandra, A.U. Mahajan, Gurpreet Singh Wander, Ashok Seth, P C Rath, Ricardo Costa, Viveka Kumar, Alexandre Abizaid, Sundeep Mishra, Vinay K. Bahl, Vijay Trehan, Ajitkumar Valaparambil, Parvin Kumar Goel, Yoshinobu Onuma, Patrick W. Serruys, Upendra Kaul, Cholenahally Nanjappa Manjunath, and Sengottuvelu Gunasekaran

Subjects
medicine.medical_specialty, medicine.anatomical_structure, business.industry, Sirolimus, Internal medicine, medicine, Cardiology, Coronary artery lesion, respiratory system, Cardiology and Cardiovascular Medicine, business, medicine.drug, Artery
Abstract

The development of fully bioresorbable vascular scaffolds (BRS) offers a new intervention strategy for coronary artery lesion by replacement of “full-metal jacket” into “full-plastic jacket”. The aim of the present study was to assess the long-term safety and performance of thin strut

Published
2018

3. TCTAP A-058 Favorable Outcomes for Systemic Pharmacokinetic Study of Sirolimus-eluting Bioresorbable Vascular Scaffold System in Treating De Novo Native Coronary Artery Lesion: A Sub Study of MeRes-1 Trial

Author

Parvin Kumar Goel, P C Rath, Viveka Kumar, A George Koshy, Upendra Kaul, Anil K. Mishra, Mathew Samuel Kalarickal, Gaurav Ganeshwala, A.U. Mahajan, Praveen Chandra, G.S. Wander, Manjunath Cholenahally Nanjappa, Ashok Seth, Ajitkumar Velaparambil Kumaran, Vinay K. Bahl, and Vijay Trehan

Subjects
medicine.medical_specialty, business.industry, fungi, Coronary artery lesion, equipment and supplies, humanities, medicine.anatomical_structure, Pharmacokinetics, Internal medicine, Sirolimus, medicine, Cardiology, cardiovascular diseases, Cardiology and Cardiovascular Medicine, business, Artery, Bioresorbable vascular scaffold, medicine.drug
Abstract

MeRes100 (Meril Life Science, Gujarat, India) is a novel Sirolimus-eluting BioResorbable Vascular Scaffold System (BRS). This sub study of MeRes-1 trial evaluated the systemic release of sirolimus from the MeRes100 BRS applied for the treatment of de novo native coronary artery lesions. The MeRes-1

Published
2017

4. TCTAP A-003 First-in-human Evaluation of a Novel Poly-L-lactide Based Sirolimus-eluting Bioresorbable Vascular Scaffold for the Treatment of De Novo Native Coronary Artery Lesions: MeRes-1 Trial

Author

P C Rath, Ashok Seth, Vijay Trehan, Viveka Kumar, Vinay K. Bahl, Praveen Chandra, G.S. Wander, Mathew Samuel Kalarickal, Upendra Kaul, Anil K. Mishra, A George Koshy, Gaurav Ganeshwala, Manjunath Cholenahally Nanjappa, A.U. Mahajan, Parvin Kumar Goel, and Ajitkumar Velaparambil Kumaran

Subjects
medicine.medical_specialty, Percutaneous, business.industry, medicine.medical_treatment, Vasomotion, First in human, Prosthesis, Surgery, Lesion, medicine.anatomical_structure, Sirolimus, Medicine, medicine.symptom, Cardiology and Cardiovascular Medicine, business, medicine.drug, Bioresorbable vascular scaffold, Artery
Abstract

The life-long presence of the metallic prosthesis interferes with the restoration of vasomotion and restricts quality lesion imaging during repeat surgical or percutaneous treatment. As a solution to this, we assessed safety and efficacy of a novel Poly-L-Lactide based Sirolimus-eluting

Published
2017

5. CRT-700.01 Favourable Outcomes for Systemic Pharmacokinetic Study of Sirolimus-Eluting BioResorbable Vascular Scaffold System in Treating de novo Native Coronary Artery Lesion: A Sub Study of MeRes-1 Trial

Author

Ashok Seth, Praveen Chandra, Vinay Kumar Bahl, Manjunath Cholenahally Nanjappa, Pratap Chandra Rath, Mathew Samuel Kalarickal, Gurpreet Singh Wander, Anil Mishra, Ajaykumar Umakant Mahajan, Ajit Kumar Velaparambil Kumaran, AGeorge Koshy, Parvin Kumar Goel, Gaurav Ganeshwala, Viveka Kumar, Upendra Kaul, and Vijay Kumar

Subjects
medicine.medical_specialty, business.industry, fungi, Coronary artery lesion, equipment and supplies, humanities, Surgery, medicine.anatomical_structure, Pharmacokinetics, Internal medicine, Sirolimus, medicine, Cardiology, cardiovascular diseases, Cardiology and Cardiovascular Medicine, business, Artery, medicine.drug, Bioresorbable vascular scaffold
Abstract

MeRes100 (Meril Life Science, Vapi, India) is a novel Sirolimus-Eluting BioResorbable Vascular Scaffold system (BRS). This sub study of MeRes-1 trial evaluated the systemic release of sirolimus from the MeRes100 BRS applied for the treatment of de novo native coronary artery lesions. The MeRes-1 is

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results